The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The real-world safety and efficacy of bispecific T-cell engager therapy in systemic AL amyloidosis
Matthew Rees, MD, St. Vincent’s Hospital, Melbourne, Australia, presents the findings of a multicenter, retrospective, real-world study evaluating the safety and efficacy of bispecific T-cell engager therapy in patients with systemic light chain (AL) amyloidosis. This therapeutic approach elicited rapid and deep hematological responses, with a high rate of early organ responses. Dr Rees highlights that, although rates of cytokine release syndrome (CRS) were low, infectious complications were frequent. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
